Related Experiment Video

Updated: Oct 17, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1

Gang Xu1, Shanshan Bu1, Xiushen Wang1

  • 1Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

International Journal of Radiation Biology
|October 8, 2021
PubMed
Abstract

Insights

MicroRNA-122 enhances radiotherapy effectiveness in hepatocellular carcinoma (HCC) by inhibiting cell proliferation and sensitizing cancer cells. Its mechanism involves regulating cyclin G1 expression, suggesting potential as a radiosensitizer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy Research

Background:

  • Radiotherapy is a key treatment for hepatocellular carcinoma (HCC).
  • MicroRNAs (miRNAs) play a role in cancer radiosensitivity.
  • MiR-122 is abundant in the liver but its role in HCC radiosensitivity is understudied.

Purpose of the Study:

  • To investigate the role of miR-122 in regulating radiosensitivity of HCC cells.
  • To explore the underlying molecular mechanisms of miR-122 in HCC radiosensitivity.

Main Methods:

  • Hepatocellular carcinoma cell lines (HepG2, Huh7) were engineered to overexpress miR-122 using lentiviral vectors.
  • Cell proliferation was assessed via MTT and colony formation assays.
  • Radiosensitivity was evaluated using a xenograft tumor model.
  • Expression of cyclin G1 mRNA and protein was quantified using qRT-PCR and Western blotting.

Main Results:

  • Overexpression of miR-122 significantly inhibited HCC cell proliferation.
  • miR-122 overexpression sensitized HCC cells to radiotherapy.
  • Suppression of cyclin G1 mRNA and protein levels was observed in HCC tumors with miR-122 overexpression.

Conclusions:

  • MiR-122 demonstrates potential as a radiosensitizer for hepatocellular carcinoma treatment.
  • The radiosensitizing effect of miR-122 in HCC is associated with the downregulation of cyclin G1.
Keywords:
Hepatocellular carcinomaMiR-122cyclin G1proliferationradiosensitivityxenograft tumor model

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.5K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.5K